Brighton, Massachusetts Clinical Trials

A listing of Brighton, Massachusetts clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 108 clinical trials
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …

growth factor
erbb1
estrogen receptor
breast cancer
cancer
Massachusetts General Hospital
 (4.8 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +6 other locations
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

kras
solid tumor
kras g12c mutation
ki-ras
metastatic malignant solid tumor
Dana Farber Cancer Institute
 (2.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +7 other locations
Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: Ipatasertib Atezolizumab

absolute lymphocyte count
lymphadenectomy
immunohistochemistry
granulocyte colony stimulating factor
lumpectomy
Dana-Farber Cancer Institute
 (2.9 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Randomized Controlled Trial of AppS to Home Monitor Your Asthma

The objective of this study is to design, implement, and evaluate the impact of an adapted health information technology(IT)-enabled practice model for asthma symptom monitoring using patient-reported outcomes (PROs) in a primary care setting. Adults over 18 years of age with asthma will be recruited at four primary care clinics …

Brigham & Women's Hospital
 (3.4 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
Cisplatin+Pembrolizumab+RT in Vulvar Cancer

This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: Cisplatin (standard of care drug) Pembrolizumab (investigational drug) Radiation Therapy (standard of care intervention)

international normalized ratio
carcinoma
aptt
blood transfusion
radical vulvectomy
Massachusetts General Hospital Cancer Center
 (4.8 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
Preoperative Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD

Prior studies have shown that left ventricular assist device (LVAD) implantation commonly results in right ventricular failure (RVF). Right ventricular dysfunction and failure after LVAD implantation is known to increase morbidity and mortality and contribute to longer post-implant hospital length of stay. Since RVF is difficult to predict and can …

ventricular dysfunction
right ventricular failure
Massachusetts General Hospital
 (4.8 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • 1 location
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the …

therapy
bortezomib
proteasome inhibitor
multiple myeloma
lenalidomide
Investigational Site Number 8400003
 (3.4 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +7 other locations
Understanding and Optimizing Care for Young Adults With Type 1 and Type 2 Diabetes Mellitus Transitioning to the Adult Diabetes Care Setting  

In this study, we will determine the feasibility of an innovative care model for young adults with diabetes and compare the primary and secondary outcomes in the innovative model to those in the usual care model for adult diabetes management at Massachusetts General Hospital (MGH) Diabetes Center.

Massachusetts General Hospital
 (4.8 away)
  • 0 views
  • 09 Dec, 2022
  • +5 other locations
In-vivo Study of the Efficacy of Hyperimmune Bovine Colostrum to Block Absorption of Gliadin Peptides in the Human Intestine: A Novel Potential Intervention for Celiac Disease and Non-celiac Gluten Sensitivity

We propose to investigate the use of hyperimmune bovine colostrum to reduce gluten absorption. A double-blind, cross-over study will be performed in which persons who are following a strict gluten-free diet will be challenged with oral gluten with or without the bovine colostrum.

Accepts healthy volunteers
Beth Israel Deaconess Medical Center
 (3.4 away) Contact site
  • 0 views
  • 27 Sep, 2022
  • +1 other locations
Identification of Predictors for Clinical Outcomes in Femoroacetabular Impingement Surgery

The overarching goal of the study is to improve the surgical treatment outcomes of FAI, which is affecting an increasing number of military personnel and young active individuals in the general population. The proposed study will investigate critical patient, disease, and surgical treatment predictors of FAI surgery outcomes.

conservative management
arthroscopy
hip arthroscopy
femoroacetabular impingement
Boston Children's Hospital
 (3.4 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +11 other locations